Influence of misoprostol (PGE1) on amniotic fluid and maternal serum adrenomedullin levels

Basit Öğe Kaydı
dc.authoridYurekli, Muhittin/0000-0002-5830-8564
dc.authorwosidInan yuksel, ESMA/V-9064-2018
dc.authorwosidYurekli, Muhittin/B-4414-2016
dc.contributor.authorHascalik, S
dc.contributor.authorCelik, O
dc.contributor.authorDogru, MI
dc.contributor.authorDogru, AK
dc.contributor.authorInan, E
dc.contributor.authorYurekli, M
dc.date.accessioned2024-08-04T20:14:57Z
dc.date.available2024-08-04T20:14:57Z
dc.date.issued2005
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective. The purpose of this study was to determine the levels of adrenomedullin (AdM) in amniotic fluid (AF) and maternal serum of misoprostol (PGE1)-induced pregnant women. Materials and methods. A total of 40 women were included in the study: 20 were in active labor and were delivered vaginally and a further 20 were not in labor and misoprostol induction was performed. Women who were undergoing labor induction received 50 mu g of misoprostol, which was placed in the posterior fornix of the vagina every 4 hrs until the onset of labor. In each patient, maternal plasma and AF samples were collected. Samples of AF were collected by transvaginal route at the time of rupture of the membranes. The labor was at the same stage in both the groups during the sample collection. In all pregnant subjects, maternal blood samples were drawn from the cubital vein at the time of AF sampling. Amniotic fluid and serum AdM concentration was measured by using reverse-phase high-performance liquid chromatography. Results. Misoprostol-induced pregnant women showed significantly higher AdM concentrations than control pregnant women in AF (79.48 +/- 6.14 pmol/ml versus 21.28 +/- 0.90 pmol/ml, P = 0.000) and maternal serum (88.20 +/- 4.34 pmol/ml versus 29.78 +/- 4.51 pmol/ml, P = 0.000). There was no significant difference between maternal serum and AF-AdM concentrations in misoprostol and control subjects. Conclusion. Increased serum and AF-AdM concentrations may be necessary to initiate cervical ripening in misoprostol-induced pregnant women.en_US
dc.identifier.doi10.1111/j.0001-6349.2005.00819.x
dc.identifier.endpage836en_US
dc.identifier.issn0001-6349
dc.identifier.issn1600-0412
dc.identifier.issue9en_US
dc.identifier.pmid16097971en_US
dc.identifier.scopus2-s2.0-24044467745en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage833en_US
dc.identifier.urihttps://doi.org/10.1111/j.0001-6349.2005.00819.x
dc.identifier.urihttps://hdl.handle.net/11616/94073
dc.identifier.volume84en_US
dc.identifier.wosWOS:000231152200002en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofActa Obstetricia Et Gynecologica Scandinavicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectadrenomedullinen_US
dc.subjectmisoprostolen_US
dc.subjectamniotic fluiden_US
dc.subjectserumen_US
dc.subjectcervical ripeningen_US
dc.titleInfluence of misoprostol (PGE1) on amniotic fluid and maternal serum adrenomedullin levelsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu